MSK e-Tumor Board: Early Detected, Low-Risk Prostate Cancer

Share
Memorial Sloan Kettering physicians present an e-tumor board, which focuses on a patient, who is otherwise well, but has a prostate-specific antigen (PSA) test at 4.6. About six weeks later, the patients PSA was rechecked, and it was 5.0. The team discusses further testing and how to approach early, low risk prostate cancer.

The e-Tumor Boards, a video series collaboration between Medscape and Memorial Sloan Kettering Cancer Center, gives physicians an inside look into a virtual multidisciplinary tumor board case discussion.

© 2023. Medscape. Used by Permission. The content of this video is the property of Medscape. and protected by U.S. and international copyright laws. You may not copy, reproduce, distribute, transmit, modify, create derivative works, or in any other way exploit any part of this copyrighted material without the prior written permission from Medscape.